CLAIMS

What is claimed:

1. ~~A method of treating cardiovascular disease or reducing the risk of cardiovascular disease in a subject, comprising administrating a fixed dose combination of a fixed dose~~Use of 120 mg or 180 mg ETC-1002 ~~or an analog thereof~~ and 2-80 mg of ~~a fixed dose of~~ one or more statins selected from the group consisting of rosuvastatin, simvastatin, pravastatin, lovastatin, fluvastatin, atorvastatin, and pitavastatin ~~or an analog thereof to~~ in the manufacture of a medicament for treating hypercholesterolemia in a subject in need thereof~~, optionally wherein ETC-1002 is administered at a fixed dose of 120 mg or at a fixed dose of 180 mg and each of the one more statins is administered at a fixed dose between 2-80 mg, and optionally wherein the method treats or reduces the risk of cardiovascular disease in the subject~~.

2. The ~~method~~ use of claim 1, wherein the medicament decreases the level of total cholesterol and non-HDL-C in the subject ~~is~~ below that of a control subject receiving placebo, a ~~fixed~~ 120 mg dose of ETC-1002, a ~~fixed~~ 180 mg dose of ETC-1002, or a ~~fixed~~ 2-80 ~~-~~mg dose ~~for each one~~ of the one or more statins.

3. The ~~method~~ use of claim 1, wherein the medicament decreases the level of low density lipoprotein (LDL) in the subject ~~is~~ below that of a control subject receiving placebo, a ~~fixed~~ 120 mg dose of ETC-1002, a ~~fixed~~ 180 mg dose of ETC-1002, or a ~~fixed~~ 2-80 ~~-~~mg dose ~~for each one~~ of the one or more statins.

4. The ~~method~~ use of claim 1, wherein the medicament decreases the number of LDL particles in the subject ~~is~~ below that of a control subject receiving placebo, a ~~fixed~~ 120 mg dose of ETC-1002, a ~~fixed~~ 180 mg dose of ETC-1002, or a ~~fixed~~ 2-80 ~~-~~mg dose ~~for each one~~ of the one or more statins.

5. The ~~method~~ use of claim 1, wherein the medicament decreases the level of apolipoprotein B (ApoB) in the subject ~~is less than~~below that of a control subject receiving placebo, a ~~fixed~~ 120 mg dose of ETC-1002, a ~~fixed~~ 180 mg dose of ETC-1002, or a 2-80 mg dose of ~~a fixed 2-80 mg dose for each one of~~ the one or more statins.

6. The ~~method~~ use of claim 1, wherein the medicament decreases the level of apolipoprotein A-1 (ApoA1) in the subject ~~is less than~~below that of a control subject receiving placebo, a ~~fixed~~ 120 mg dose of ETC-1002, a ~~fixed~~ 180 mg dose of ETC-1002, or a ~~fixed~~ 2-80 ~~-~~mg dose ~~for each one~~ of the one or more statins.

~~7.~~ The ~~method~~ use of claim 1, wherein the medicament decreases the ratio of apolipoprotein B (ApoB) to apolipoprotein A-1 (ApoA1) in the subject ~~is~~ below that of a control subject receiving placebo, a ~~fixed~~ 120 mg dose of ETC-1002, a ~~fixed~~ 180 mg dose of ETC-1002, or a ~~fixed~~ 2-80 ~~-~~mg dose ~~for each one~~ of the one or more statins.

~~8.~~7. ~~The method of claim 1, wherein the one or more statins is selected from the group consisting of rosuvastatin, simvastatin, pravastatin, lovastatin, fluvastatin, fluvastatin, and pitavastatin.~~

~~9.~~8. The ~~method~~ use of claim 1, wherein the subject has ~~hypercholesterolemia~~atherosclerotic cardiovascular disease.

~~10.~~9. The ~~method~~ use of claim 1, wherein the subject ~~is an animal~~has familial hypercholesterolemia.

~~11.~~10. The ~~method~~ use of claim 1, wherein the subject is human.

~~12.~~11. A ~~therapeutic composition~~fixed-dose combination comprising a therapeutic amount of ~~a fixed dose of~~ ETC-1002 and ~~a fixed dose for each one of~~ one or more statins selected from the group consisting of rosuvastatin, simvastatin, pravastatin, lovastatin, fluvastatin, atorvastatin, and pitavastatin.

~~13.~~12. The ~~composition~~ fixed-dose combination of claim 11~~2~~, wherein the ~~dose is between 2-80 mg of one statin~~amount of each of the one or more statins is 2-80 mg.

~~14.~~13. The ~~composition~~ fixed-dose combination of claim 11~~2~~, wherein the amount of ETC-1002 is ~~a~~ 120 mg or 180 mg ~~dose of ETC-1002~~ and ~~a fixed 2-80 mg dose for each one of one or more statins~~the amount of each of the one or more statins is 2-80 mg.

~~15. The composition of claim 12, wherein the dose is between 40-80 mg of one statin.~~

14. ~~16. The composition of claim 12, wherein the one or more statins is selected from the group consisting of rosuvastatin, simvastatin, pravastatin, lovastatin, fluvastatin, fluvastatin, and pitavastatin.~~Use of 120 mg or 180 mg ETC-1002 and 2-80 mg of one ore more statins selected from the group consisting of rosuvastatin, simvastatin, pravastatin, lovastatin, fluvastatin, atorvastatin, and pitavastatin in the manufacture of a medicament for lowering low density lipoprotein-cholesterol (LDL-C) in a subject in need thereof.

15. The use of claim 14, wherein the subject has atherosclerotic cardiovascular disease.

16. The use of claim 14, wherein the subject has familial hypercholesterolemia.

17. The use of claim 14, wherein the medicament decreases the level of total cholesterol and non-HDL-C in the subject below that of a control subject receiving placebo, a 120

mg dose of ETC-1002, a 180 mg dose of ETC-1002, or a 2-80 mg dose of the one or more statins.

18. The use of claim 14, wherein the medicament decreases the level of low density lipoprotein (LDL) in the subject below that of a control subject receiving placebo, a 120 mg dose of ETC-1002, a 180 mg dose of ETC-1002, or a 2-80 mg dose of the one or more statins.

19. The use of claim 14, wherein the medicament decreases the number of LDL particles in the subject below that of a control subject receiving placebo, a 120 mg dose of ETC-1002, a 180 mg dose of ETC-1002, or a 2-80 mg dose of the one or more statins.

20. The use of claim 14, wherein the medicament decreases the level of apolipoprotein A-1 (ApoA1) in the subject below that of a control subject receiving placebo, a 120 mg dose of ETC-1002, a 180 mg dose of ETC-1002, or a 2-80 mg dose of the one or more statins.

21. The use of claim 14, wherein the medicament decreases the level of total cholesterol and non-HDL-C in the subject below that of a control subject receiving placebo, a 120 mg dose of ETC-1002, a 180 mg dose of ETC-1002, or a 2-80 mg dose of one or more statins.

22. The use of claim 14, wherein the medicament decreases the ratio of apolipoprotein B (ApoB) to apolipoprotein A-1 (ApoA1) in the subject below that of a control subject receiving placebo, a 120 mg dose of ETC-1002, a 180 mg dose of ETC-1002, or a 2-80 mg dose of the one or more statins.

23. The use of any one of claims 1-10 and 14-22, wherein the amount of ETC-1002 is 120 mg.

24. The use of any one of claims 1-10, and 14-22, wherein the amount of ETC-1002 is 180 mg.

25. The use of claim 23, wherein the one or more statins is rosuvastatin; and the amount of rosuvastatin is 5-40 mg.

26. The use of claim 24, wherein the one or more statins is rosuvastatin; and the amount of rosuvastatin is 5-40 mg.

27. The use of claim 23, wherein the one or more statins is simvastatin; and the amount of simvastatin is 10-80 mg.

28. The use of claim 24, wherein the one or more statins is simvastatin; and the amount of simvastatin is 10-80 mg.

29. The use of claim 23, wherein the one or more statins is pravastatin; and the amount of pravastatin is 10-80 mg.

30. The use of claim 24, wherein the one or more statins is pravastatin; and the amount of pravastatin is 10-80 mg.

31. The use of claim 23, wherein the one or more statins is lovastatin; and the amount of lovastatin is 20-40 mg.

32. The use of claim 24, wherein the one or more statins is lovastatin; and the amount of lovastatin is 20-40 mg.

33. The use of claim 23, wherein the one or more statins is fluvastatin; and the amount of fluvastatin is 20-80 mg.

34. The use of claim 24, wherein the one or more statins is fluvastatin; and the amount of

fluvastatin is 20-80 mg.

35. The use of claim 23, wherein the one or more statins is pitavastatin; and the amount of pitavastatin is 1-4 mg.

36. The use of claim 24, wherein the one or more statins is pitavastatin; and the amount of pitavastatin is 1-4 mg.

37. The use of claim 23, wherein the one or more statins is atorvastatin; and the amount of atorvastatin is 10-80 mg.

38. The use of claim 24, wherein the one or more statins is atorvastatin; and the amount of atorvastatin is 10-80 mg.

39. The fixed-dose combination of any one of claims 11-13, wherein the amount of ETC-1002 is 120 mg.

40. The fixed-dose combination of any one of claims 11-13, wherein the amount of ETC-1002 is 180 mg.

41. The fixed-dose combination of claim 39, wherein the one or more statins is rosuvastatin; and the amount of rosuvastatin is 5-40 mg.

42. The fixed-dose combination of claim 40, wherein the one or more statins is rosuvastatin; and the amount of rosuvastatin is 5-40 mg.

43. The fixed-dose combination of claim 39, wherein the one or more statins is simvastatin; and the amount of simvastatin is 10-80 mg..

44. The fixed-dose combination of claim 40, wherein the one or more statins is simvastatin; and the amount of simvastatin is 10-80 mg.

45. The fixed-dose combination of claim 39, wherein the one or more statins is pravastatin; and the amount of pravastatin is 10-80 mg.

46. The fixed-dose combination of claim 40, wherein the one or more statins is pravastatin; and the amount of pravastatin is 10-80 mg.

47. The fixed-dose combination of claim 39, wherein the one or more statins is lovastatin; and the amount of lovastatin is 20-40 mg.

48. The fixed-dose combination of claim 40, wherein the one or more statins is lovastatin; and the amount of lovastatin is 20-40 mg.

49. The fixed-dose combination of claim 39, wherein the one or more statins is fluvastatin; and the amount of fluvastatin is 20-80 mg.

50. The fixed-dose combination of claim 40, wherein the one or more statins is fluvastatin; and the amount of fluvastatin is 20-80 mg.

51. The fixed-dose combination of claim 39, wherein the one or more statins is pitavastatin; and the amount of pitavastatin is 1-4 mg.

52. The fixed-dose combination of claim 40, wherein the one or more statins is pitavastatin; and the amount of pitavastatin is 1-4 mg.

53. The fixed-dose combination of claim 39, wherein the one or more statins is atorvastatin; and the amount of atorvastatin is 10-80 mg.

54. The fixed-dose combination of claim 40, wherein the one or more statins is atorvastatin; and the amount of atorvastatin is 10-80 mg.